Slide 1: EYP-1901 DAVIO Study Interim Results
1 | EYEPOINT PHARMACEUTICALS Delivering Innovation to the Eye EYP-1901 DAVIO Study Interim Results November 13, 2021 Exhibit 99.2
Slide 2: Forward-looking statements
Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments
Slide 3: Company Overview: Pipeline leveraging proven Durasert technology
COMPANY OVERVIEW Pipeline leveraging proven Durasert® technology * Compelling pipeline focused on retinal disease EYP-1901 - advancing into phase 2 trials for wet AMD, diabetic retinopathy (DR), and retinal vein occlusion (RVO) after positive phase 1 top line results YUTIQ50 – potential six month tr
Slide 4: EYP-1901 - Vorolanib in bioerodible Durasert
EYP-1901 - Vorolanib in bioerodible Durasert® Our goal is nothing short of transforming the treatment of wet AMD, diabetic retinopathy, and retinal vein occlusion PIPELINE 4 | EYEPOINT PHARMACEUTICALS
Slide 5: Real world need: today's wet AMD treatments still result in vision loss
Real world need... today's wet AMD treatments still result in vision loss over time PIPELINE EYP-1901 Adjusted Mean Change From Baseline in VA Letter Score 3 6 12 Month 12 p=0.67† Aflibercept Ranibizumab 1.52 1.01 -0.19 1.24 0.71 -0.30 Follow-up (Month) Lotery et al., Eye (2017) 31, 1697–1706 RETROS
Slide 6: Real World Reality: Even One Missed Injection Can Mean Loss of Vision
PIPELINE EYP-1901 RETROSPECTIVE STUDY OF 3350 RANIBIZUMAB AND 4300 AFLIBERCEPT TREATMENT-NAIVE EYES WITH WET AMD 6 | EYEPOINT PHARMACEUTICALS Real World Reality – Even One Missed Injection Can Mean Loss of Vision Study evaluated 1,041 pts getting intravitreal anti-VEGF therapies 60% went to schedule
Slide 7: EYP-1901 – A Novel Approach to Wet AMD Therapy
EYP-1901 – A Novel Approach to Wet AMD Therapy Vorolanib in Durasert® (bioerodible) 7 Vorolanib Receptor-binding, small molecule tyrosine kinase inhibitor (TKI) Activity against all isoforms of VEGF and PDGF Oral vorolanib previously studied in a wet AMD ph1 and ph2 programs1,2 Strong efficacy signa
Slide 8: Bioerodible Durasert Platform: injectable, sustained-delivery system
Bioerodible Durasert® Platform: injectable, sustained-delivery system Similar to YUTIQ®, Retisert®, and Vitrasert® Main difference: No polyimide shell Bioerodible Drug release dynamics Initial burst near the surface of implant Constant, zero-order kinetic release rate for months EYP-1901 – A Novel A
Slide 9: Effective blocking of VEGFR Prevents Exudation and Loss of Vision
23 | EYEPOINT PHARMACEUTICALS Effective blocking of VEGFR Prevents Exudation and Loss of Vision PIPELINE EYP-1901 VEGF-B VEGF-C VEGF-D VEGF-A R1 / INFLAMMATION R2 / BLOOD VESSEL LEAKAGE R3 / BLOOD VESSEL GROWTH & LEAKAGE VEGF SIGNALING PATHWAYS VOROLANIB 9 | EYEPOINT PHARMACEUTICALS Other Anti-VEGF-
Slide 10: EYP-1901 phase 1 trial interim results
EYP-1901 phase 1 trial interim results 10 | EYEPOINT PHARMACEUTICALS
Slide 11: DAVIO Phase 1 Study Interim Data Summary: all objectives met
All objectives successfully met Positive safety data: No ocular Serious Adverse Events (SAEs) reported No drug-related systemic SAEs reported All ocular AEs were < grade 2; the only grade 3 AE was not drug-related EFFICACY Positive Efficacy Data: Stable VA and OCT Median time to rescue: 6 months Cli
Slide 12: DAVIO study design: no mandated retreatments
NO mandated EYP 1901 retreatments Criteria for rescue anti-VEGF therapy*: New fluid > 75 microns (OCT) compared to Day-0 2 lines of BCVA secondary to wet AMD compared to Day-0 New macular hemorrhage secondary to wet AMD *at the discretion of the investigator Enrollment Previously treated wet AMD eye
Slide 13: EYP-1901 Phase 1 DAVIO Participants and Follow-Up
BCVA: best corrected visual acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; CST: central subfield thickness 13 | EYEPOINT PHARMACEUTICALS EYP-1901 Phase 1 DAVIO Participants and Follow-Up
Slide 14: Results: Safety
14 | EYEPOINT PHARMACEUTICALS Results: Safety
Slide 15: DAVIO Primary Endpoint – Safety: Positive Overall Safety Data
No other reported significant adverse events such as: No vitreous floaters No endophthalmitis No retinal detachment No implant migration in the anterior chamber No retinal vasculitis No posterior segment inflammation AC, anterior chamber; AE, adverse event; BCVA, best corrected visual acuity; SAE, s
Slide 16: DAVIO Summary to Date – Ocular Safety
a. All mild-to-moderate in severity and determined not related to study drug b. Grade 1/Mild AEs of particular interest AC anterior chamber; AE, adverse event; BCVA, best corrected visual acuity; OS, left eye; OU; both eyes 16 | EYEPOINT PHARMACEUTICALS DAVIO Summary to Date – Ocular Safety
Slide 17: Results: Visual acuity, CST, Rescue Free rates, and Reduction in Treatment Burden
17 | EYEPOINT PHARMACEUTICALS Results: Visual acuity, CST, Rescue Free rates, and Reduction in Treatment Burden
Slide 18: Results: Average Visual Acuity Stable
Results: Average Visual Acuity (VA) Stable 6 Months After Treatment 18 BCVA: best corrected visual acuity Interim data – monitored through 4 months For all 17 eyes at 6 months VA = -2.5 letters
Slide 19: Results: Central Subfield Thickness (CST)
OCT: optical coherence tomography; CST: central subfield thickness Interim data – monitored through 4 months 19 | EYEPOINT PHARMACEUTICALS Results: Central Subfield Thickness (CST) Sustainable Anatomical Control & Efficacy For all 17 eyes at 6 months CST on OCT = - 2.7 microns
Slide 20: Rescue-free Rates up to Each Visit: Entire Study Group
Interim data – monitored through 4 months 20 | EYEPOINT PHARMACEUTICALS Rescue-free Rates up to Each Visit: Entire Study group Median Time to Rescue = 6 Months
Slide 21: Rescue-free Rates up to Each Visit
Interim data – monitored through 4 months 21 | EYEPOINT PHARMACEUTICALS Rescue-free Rates up to Each Visit Median Time to Rescue = 6 Months 8 of 17 eyes remain rescue-free at 6 months
Slide 22: Details on Patients That Received Rescue Anti-VEGF Therapy
Details on Patients (n=9) That Received Rescue Anti-VEGF Therapy CST: central subfield thickness; SRF: subretinal fluid; IRF: intra-retinal fluid CST’s NOT Reading Center Confirmed - Interim data – monitored through 4 months
Slide 23: Results: Clinically Significant Reduction in Treatment Burden
SOC Anti-VEGF Injections Before and After Treatment SoC (Anti-VEGF) + EYP1901 ● Anti-VEGF ○ No rescue injection given ☐ Missed visit months 23 | EYEPOINT PHARMACEUTICALS Results: Clinically Significant Reduction in Treatment Burden 79 % for the entire cohort Interim data – monitored through 4 months
Slide 24: Results: Clinically Significant Reduction in Treatment Burden of 79%
SOC Anti-VEGF Injections Before and After Treatment Results: Clinically Significant Reduction in Treatment Burden of 79 % for the Entire Cohort SoC (Anti-VEGF) + EYP1901 ● Anti-VEGF ○ No rescue injection given ☐ Missed visit months Interim data – monitored through 4 months
Slide 25: Treatment Burden After EYP1901
Treatment Burden After EYP1901 Substantial and Highly Clinically Relevant Reduction Reduction in Treatment Burden at 6 months post-treatment 100 % reduction = no rescue through 6 months 25 | EYEPOINT PHARMACEUTICALS Treatment Burden After EYP1901 Substantial and Highly Clinically Relevant Reduction
Slide 26: Case 1: Entered Dry, Stayed Dry for 9 Months
Screening Visit: 6 anti-VEGF injections prior to enrollment Initial Diagnosis: 9 months prior to enrollment Screening visits prior to treatment 26 | EYEPOINT PHARMACEUTICALS Case 1: Entered Dry, Stayed Dry for 9 Months Low dose cohort (EYP-1901 440 µg)
Slide 27: Case 1: Post-Treatment (No Rescues Through Month 9)
Month 5 – no rescue 27 | EYEPOINT PHARMACEUTICALS Case 1: Post-Treatment (No Rescues Through Month 9) Low dose cohort (EYP-1901 440 µg)
Slide 28: Case 2: Rescued at Month 1
Screening Visit (9 prior anti-VEGF injections) Prior to Treatment 28 | EYEPOINT PHARMACEUTICALS Case 2: Rescued at Month 1 Failure of Both SOC therapy and EYP 1901 Low dose cohort (EYP-1901 440 µg) Significant intraretinal fluid
Slide 29: Case 2: Reduced treatment burden by 34% despite early rescue
Case 2: 9 anti-VEGF injections prior to screening Low Dose Cohort (EYP-1901 440 µg) Despite early rescue, EYP1901 still reduced treatment burden by 34% Month 1 – Rescue 8 weeks post Eylea #1 12 weeks post EYP1901 5 weeks post Eylea 4 weeks post EYP1901 4 weeks post Eylea 16 weeks post EYP1901 8 week
Slide 30: Case 3: Entered the Study With Subretinal Fluid
30 | EYEPOINT PHARMACEUTICALS Screening Visit (8 prior anti-VEGF injections) Prior to treatment Case 3: Entered the Study With Subretinal Fluid High dose cohort (EYP-1901 3090 µg)
Slide 31: Case 3: Post-treatment – New Fluid Doesn't Mean Rescue
31 | EYEPOINT PHARMACEUTICALS Case 3: Post-treatment – New Fluid Doesn’t Mean Rescue ! High dose cohort (EYP-1901 3090 µg)
Slide 32: DAVIO Summary: EYP-1901 Phase 1 Clinical Trial Met All Objectives
All objectives successfully met: Proof of Concept for Vorolanib in wet AMD Positive Safety Data No ocular SAEs reported No drug-related systemic SAEs reported Ocular AEs - majority mild and to be expected EFFICACY Positive Efficacy Data: Stable VA and OCT Median time to rescue: 6 months 76 % rescue-
Slide 33: Key Takeaways for EYP-1901 from DAVIO Study
Key Takeaways for EYP-1901 from DAVIO Study 33 | EYEPOINT PHARMACEUTICALS EYP-1901 (vorolanib delivered with our bioerodible DURASERT) - favorable safety and tolerability profile Proof of Concept - clinically significant activity of vorolanib in wet AMD setting Demonstrated ability of DURASERT techn
Slide 34: Next Steps for EYP-1901
Key Takeaways for EYP-1901 from DAVIO Study 34 | EYEPOINT PHARMACEUTICALS Advance EYP-1901 into three Phase 2 clinical trials by YE:2023 Wet AMD initiation expected in 2022, Diabetic Retinopathy initiation expected in 2022, and Retinal Vein Occlusion initiation expected by 2023 FDA Type C meeting in
Slide 35: Post-Hoc Analysis of OCT Biomarkers – Intraretinal Fluid
35 | EYEPOINT PHARMACEUTICALS Refine Phase 2 Trial - Post-Hoc Analysis of OCT Biomarkers – Wet AMD eyes with intraretinal fluid (IRF) - poor prognosis DAVIO enrolled four subjects with foveal IRF at Screening
Slide 36: Post-hoc Analysis of Rescue-Free Rates for Eyes with No Foveal IRF
36 | EYEPOINT PHARMACEUTICALS Post-hoc Analysis of Rescue-Free Rates for Eyes with No Foveal Intraretinal Fluid (IRF) - N=13 Rescue-free rate up to each visit for eyes w no IRF Interim data – monitored through 4 months
Slide 37: Post-hoc Results: 91% reduction in treatment burden
SoC (Anti-VEGF) + EYP1901 months ● Anti-VEGF ○ No rescue injection given ☐ Missed visit 37 | EYEPOINT PHARMACEUTICALS Post-hoc Results: 91% reduction in treatment burden Excluding four patients with foveal intraretinal fluid at Screening SOC Anti-VEGF Injections Before and After Treatment Interim da
Slide 38: EyePoint 2022+ — Positioned to Transform the Ophthalmology Landscape
EyePoint 2022+ — Positioned to Transform the Ophthalmology Landscape 38 | EYEPOINT PHARMACEUTICALS Paradigm-shifting potential of DURASERT technology now demonstrated with multiple approved drugs and small molecule agents Ability to harness technology for small molecule agents with different MOAs Ab
Slide 39: Most Compelling Data from DAVIO
SOC Anti-VEGF Injections Before and After Treatment SoC (Anti-VEGF) + EYP1901 ● Anti-VEGF ○ No rescue injection given ☐ Missed visit months 39 | EYEPOINT PHARMACEUTICALS Most Compelling Data from DAVIO - Clinically Significant Reduction in Treatment Burden of 79 % for the entire cohort Interim data
Slide 40: Delivering Innovation to the Eye
1 | EYEPOINT PHARMACEUTICALS Delivering Innovation to the Eye